
CapsoVision Inc (CV) Stock Forecast & Price Target
CapsoVision Inc (CV) Analyst Ratings
Bulls say
CapsoVision Inc. has achieved significant milestones with its CapsoCam Plus device, being utilized in over 135,000 procedures and generating nearly $12 million in revenue for 2024. The consistent annual revenue growth since the company's launch in the U.S. demonstrates a robust demand for its innovative endoscopic video imaging technology. With a solid market presence in gastrointestinal imaging and ongoing development of the CapsoColon 3D for the large intestines, CapsoVision holds a favorable outlook for future expansion and profitability.
Bears say
CapsoVision Inc faces significant challenges that may impede its revenue growth, primarily due to resistance from healthcare providers and patients concerning the retrieval of its endoscopic capsules, which could delay the path to profitability. Furthermore, potential disruptions in manufacturing, adverse clinical outcomes, or product recalls may lead to diminished investor confidence and negatively affect revenue streams. Lastly, the need for CE mark approval may constrain the market availability of CapsoCam Plus, especially as the company seeks to expand into pediatric applications and fully digestible technologies.
This aggregate rating is based on analysts' research of CapsoVision Inc and is not a guaranteed prediction by Public.com or investment advice.
CapsoVision Inc (CV) Analyst Forecast & Price Prediction
Start investing in CapsoVision Inc (CV)
Order type
Buy in
Order amount
Est. shares
0 shares